Eliem Therapeutics
ELYM | NASDAQ
$5.11
-$0.05 (-0.97%)
At close: Oct 02, 2024, 04:00 PM ET
Eliem Therapeutics Company Profile
Company profile explainedCompany Profile
Eliem Therapeutics, Inc. is a clinical-stage biotechnology firm focused on developing therapeutic solutions for conditions characterized by abnormal neuronal excitability. The company aims to fulfill significant unmet medical needs in areas such as chronic pain management, neuropsychiatric illnesses, epilepsy, and other disorders affecting the central and peripheral nervous systems. Their developmental pipeline is highlighted by two primary drug candidates. ETX-810 is currently in Phase IIa clinical studies for the treatment of chronic pain. The second key candidate, ETX-155, is undergoing Phase I clinical trials, with potential applications for major depressive disorder, perimenopausal depression, and focal onset seizures. Beyond these lead assets, Eliem is also cultivating several preclinical programs, including a Kv7 Program targeting pain, epilepsy, and depression, and an Anxiolytic program specifically designed for generalized anxiety disorder. Eliem Therapeutics, Inc. was established in 2018 and is headquartered in Redmond, Washington.
Key Executives
| Name | Position |
|---|---|
| Aoife Brennan BCh MMSc | Chief Executive Officer, President & Director |
| Brett Kaplan | Chief Operating Officer & Principal Financial Officer |
| Andrew Levin | Principal Financial Officer, Co-Founder & Executive Chairman |
| Emily Pimblett | Chief Accounting Officer |
| Jo Palmer-Phillips | Chief Development Officer |
| Nishi Rampal | Senior Vice President of Clinical Development |
| Valerie Morisset | Chief Scientific Officer and Executive Vice President of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 30, 2026 | 4 | Filing |
| Sep 17, 2026 | 4 | Filing |
| Sep 03, 2026 | 8-K | Current Report |
| Aug 14, 2026 | 8-K | Current Report |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jul 08, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 07, 2026 | SC 13D/A | [Amend] Filing |
| Jul 01, 2026 | 4 | Filing |
| Jul 01, 2026 | 4 | Filing |
Eliem Therapeutics
| Country | United States |
| IPO Date | Aug 10, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Aoife M. Brennan BAO, BCh, MB, MMSc |
Contact Details
23515 NE Novelty Hill Road Redmond,
Washington 98053 United States
Stock Details
| Ticker Symbol | ELYM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001768446 |
| CUSIP Number | 28658R106 |
| ISIN Number | US28658R1068 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove ELYM